Skip to main content
Clinical Trials/NCT01004289
NCT01004289
Completed
Phase 2

POSTconditioning During Coronary Angioplasty in Acute Myocardial Infarction Study (POST-AMI)

University of Padova1 site in 1 country78 target enrollmentApril 2007

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Myocardial Reperfusion Injury
Sponsor
University of Padova
Enrollment
78
Locations
1
Primary Endpoint
Infarct size estimated by magnetic resonance
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

The POST-conditioning during coronary angioplasty in Acute Myocardial Infarction (POST-AMI) trial will evaluate the usefulness of postconditioning in limiting infarct size and microvascular damage during the early and late phases after AMI.

Detailed Description

POST-AMI is a single-center, prospective, randomized trial, with a planned inclusion of 78 patients with ST-elevation Acute Myocardial Infarction (AMI). Patients will be randomly assigned to postconditioning arm (primary angioplasty (PA) and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion) or non-postconditioning arm (PA and stenting without additional intervention). All patients will be treated medically according to current international guidelines, including glycoprotein IIb/IIIa inhibitors before PCI. The primary end point is to evaluate whether postconditioning, compared to PA without additional intervention, reduces infarct size estimated by magnetic resonance at 30±10 days after the AMI. Secondary end points are microvascular obstruction observed at magnetic resonance, ST-segment elevation resolution, persistent ST-segment elevation, angiographic myocardial blush grade \<2 and non sustained/sustained ventricular tachycardia in the 48 hours following PA. Further secondary end points are enzymatic infarct size, left ventricular remodeling and left ventricular function at magnetic resonance performed at 6±1 months, and the reduction of major adverse cardiac events at 30 days and 6 months.

Registry
clinicaltrials.gov
Start Date
April 2007
End Date
April 2010
Last Updated
15 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University of Padova

Eligibility Criteria

Inclusion Criteria

  • clinical evidence of myocardial infarction defined by the presence of ischemic chest pain lasting more than 30 minutes, with a time interval from the onset of symptoms less than 6 hours before hospital admission, associated with typical ST-segment elevation on the 12-lead ECG
  • angiographic-detected culprit lesion with stenosis diameter \>70% and TIMI flow grade \<=1

Exclusion Criteria

  • previous acute myocardial infarction
  • previous myocardial revascularization (angioplasty or coronary bypass)
  • previous heart valve replacement
  • previous heart transplant
  • clinical instability precluding the suitability of the study
  • cardiogenic shock or persistent hypotension (systolic blood pressure \<100 mmHg)
  • rescue angioplasty after thrombolytic therapy
  • evidence of coronary collaterals (Rentrop grade\>0) in the risk area
  • advanced atrioventricular block
  • significant bradycardia

Outcomes

Primary Outcomes

Infarct size estimated by magnetic resonance

Time Frame: 30±10 days after myocardial infartion

Secondary Outcomes

  • Non sustained/sustained ventricular tachycardia(Within 48 hours after miocardial infarction)
  • Enzymatic infarct size(Within 7 days after myocardial infarction)
  • ST-segment elevation resolution(First post-intervention ECG)
  • Persistent ST-segment elevation(At 24 and 48 hours post-intervention ECG)
  • Angiographic myocardial blush grade <2(After primary angioplasty)
  • Microvascular obstruction observed at magnetic resonance(30±10 days after myocardial infarction)
  • Left ventricular remodeling and left ventricular function at MRI(At 6±1 months)
  • Incidence of Major Adverse Cardiac Events (MACE), defined as the combination of death, re-infarction, re-hospitalization for heart failure or repeat revascularization(At 30 days and at 6 months)

Study Sites (1)

Loading locations...

Similar Trials